Research programme: antibacterial therapeutics - Spero Therapeutics/Pro Bono Bio

Drug Profile

Research programme: antibacterial therapeutics - Spero Therapeutics/Pro Bono Bio

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Pro Bono Bio
  • Developer Pro Bono Bio; Spero Therapeutics
  • Class Antibacterials; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 31 Jan 2017 Preclinical trials in Gram-negative infections in USA (unspecified route) before January 2017
  • 31 Jan 2017 Spero Therapeutics acquires antibacterial therapeutics from Pro Bono Bio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top